Sigachi Industries Submits CEP Filing for Propafenone Hydrochloride, Aims to Expand Revenue Channels

Sigachi Industries Limited, a leading player in the pharmaceutical industry, has announced the submission of a CEP filing for 'Propafenone Hydrochloride'. This move is a significant step towards ensuring European regulatory standards and highest levels of product quality and safety. The Propafenone Hydrochloride, widely used in the treatment of cardiac arrhythmias, is a high-demand API with a current global market size of USD 1.2 billion and is projected to reach USD 2.1 billion by 2032. The company is committed to delivering excellence through advanced manufacturing capabilities and catering to the needs of highly regulated markets, including the EU, ensuring compliance and highest quality standards.